Friday, 24 October 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 24 October 2025
News

Who's on the Nov PBS wish list?

 Posted 22 October 2025 AM

Thirteen drugs are ripe for PBS reimbursement from November - including nine which are considered new listings - as companies line up for the second last funding round for 2025.

AstraZeneca is hoping for a fast turnaround for its Imfinzi/Imjudo combo to be used in patients with  advanced (unresectable) Stage B Barcelona Clinic Liver Cancer or Stage C hepatocellular carcinoma who have not received prior treatment or who are intolerant to prior treatment with a tyrosine kinase inhibitor.

To see the whole article, please login

Popular

What Drs truly think of pharma
Country Leader quits for new role
Who's on the Nov PBS wish list?
'Not a coup': Novo cleans out board
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (1)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home